



Express Mail No.: EL 477 035 523 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Francisco et al.

Serial No.: 09/724,406

Art Unit: 1642

Filed: November 28, 2000

Examiner: Davis, N.

For: RECOMBINANT ANTI-CD30  
ANTIBODIES AND USES THEREOF

Attorney Docket No.: 9632-006-999

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

TECH CENTER 1600/2900

MAR 25 2002

RECEIVED

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references BM-BO listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references BM-BO are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art". As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited by Applicant" instead of "List of Prior Art Cited".

Pursuant to 37 C.F.R. § 1.97(c)(2), since this second Supplemental Information Disclosure Statement is being submitted after the first Office Action on the merits but before a final Office Action under 37 C.F.R. § 1.113, a fee of \$180.00 is believed to be due. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.


Respectfully submitted,

Date: March 18, 2002

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosure

 <b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.		APPLICATION NO.	
					9632-006-999		09/724,406	
					APPLICANT			
					Francisco et al.			
FILING DATE					GROUP			
November 28, 2000					1642			
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES NO	
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	BM	Bauer <i>et al.</i> , 1999, "Immunotherapy of Human Tumors with T-Cell-activating Bispecific Antibodies: Stimulation of Cytotoxic Pathways <i>in Vivo</i> ," Cancer Research, 59:1961-65.						
	BN	Pohl <i>et al.</i> , 1993, "CD30-Antigen-Specific Targeting and Activation of T Cells Via Murine Bispecific Monoclonal Antibodies Against CD3 and CD28: Potential Use for the Treatment of Hodgkin's Lymphoma," Int. J. Cancer 54:820-27.						
	BO	Renner and Pfreundschuh, 1995, "Tumor Therapy by Immune Recruitment with Bispecific Antibodies," Immunology Reviews, 145:178-209.						
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

 RECEIVED  
 MAR 25 2002  
 TECH CENTER 1600/2909